Jazz Pharmaceuticals acquires Chimerix (CMRX) for $935M, adding ONC201, a promising brain cancer drug. Find out why I believe ...

Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately ...

Jazz Pharmaceuticals will acquire biotech firm Chimerix for about $935 million in cash to gain access to its lead drug ...

JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.

Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

In a deal worth approximately $935m, Jazz Pharmaceuticals is set to acquire Chimerix, a biotechnology company developing ...

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in ...

Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO ...

Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma.

Jazz Pharmaceuticals said Wednesday it would spend nearly $1 billion to buy Chimerix and its experimental pill for a ...

At the heart of the deal is the drug candidate dordaviprone, which is months away from a regulatory verdict for its use in H3 ...